Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Diprivan
Synonyms :
propofol
Class :
General anesthetic
Brand Name :
Diprivan
Synonyms :
propofol
Class :
General anesthetic
Dosage Forms & Strengths
Injectable solution
10mg/ml
Initial Dose:
Solution
Intravenous (IV)
every 10 second
<55 years-ASA I/II:40mg Intravenous every 10 sec
Not premedicated with intramuscular opioids or benzodiazepines:2-2.5mg/kg Intravenous
>55 years-ASA III/IV: 20mg Intravenous every 10 sec
Maintenance Dose
<55 years-ASA I/II:0.1-0.2 mg/kg/min Intravenous
Intermittent bolus-Increase 2.5-5ml
>55 years-ASA III/IV:0.05-0.1 mg/kg/min Intravenous
Initial Dose:
0.1 - 0.15
mg/kg/min
Intravenous (IV)
for 3- 5min
Over 3-5 Mins, administer 0.5mg/kg
Maintenance Dose
0.025-0.075mg/kg/min IV for the first 10-15 min
Intermittent bolus:10-20mg increments
Elderly:0.02-0.06mg/kg/min Intravenous
ICU Patient:
Solution
Intravenous (IV)
as needed
Initial dose
0.005mg/kg/min Intravenous for 5 mins
Increase by 5-10mcg/kg/min for 5-10mins
Maintenance Dose
0.005mg/kg/min Intravenous for 5 mins
0.005mg/kg/min increase every 5 min
Dosage Forms & Strengths
Injectable solution
10mg/ml
Initial Dose:
3-16 years-ASA I/II:2.5-3.5 mg/kg Intravenous for 20-30 sec
<3 years-not recommended
Maintenance dose
2 months-16 years-ASA I/II:0.125-0.3mg/kg/min
Refer adult dosing
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
CYP3A4 Inducers: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inducers: they may diminish the serum concentration of hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may increase the serum concentration of colchicine
may increase the serum concentration of CYP3A4 substrates
may enhance the CNS depressant effect
may enhance the serum concentration
may diminish the serum concentration
may diminish the serum concentration
budesonide and formoterol (inhalation)
may enhance the serum concentration of CYP3A4 inhibitor
may enhance serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration when combined with abiraterone acetate
may diminish serum concentrations when combined with aripiprazole lauroxil
may diminish the serum concentration when combined with brexpiprazole
belumosudil :they may diminish the serum concentration of CYP3A4 Inducers
clopidogrel: they may enhance serum concentrations of CYP2C19 Inducers
etoposide: they may diminish the serum concentration of CYP3A4 inducers
may enhance the concentration when combined with serum of selexipag
It may increase the arrhythmogenic effect when combined with epinephrine (Systemic)
atogepant: they may diminish the serum concentration of CYP3A4 Inducers
praziquantel: they may diminish the serum concentration of CYP3A4 Inducers
ubrogepant: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
may enhance the concentration of serum when combined with treprostinil
may diminish the concentration of serum when combined with daclatasvir
may diminish the concentration of serum when combined with duvelisib
may diminish the concentration of serum when combined with ganaxolone
may diminish the concentration of serum when combined with glasdegib
may diminish the concentration of serum when combined with guanfacine
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with indinavir
may diminish the concentration of serum when combined with larotrectinib
may diminish the concentration of serum when combined with lefamulin
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
it enhances by affecting the hepatic enzyme CYP2B6 metabolism
it enhances by affecting the hepatic enzyme CYP2B6 metabolism
may affect the unspecified interaction mechanism
it decreases by affecting the hepatic enzyme CYP2B6 metabolism
it enhances by affecting the hepatic enzyme CYP1A2 metabolism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may diminish the concentration of serum when combined with antihepaciviral products
azelastine may enhance the CNS depressant effect of CNS Depressants
CNS depressants increase the effect of orphenadrine
it increases the effect of CNS depressants
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the effect of flunarizine
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in serum
they decrease the concentration of doravirine in the serum
it increases the effect of CNS depressants
it increases the concentration of CYP3A4 substrates in the serum
may diminish the serum concentration
may diminish the serum concentration
they decrease the concentration of rilpivirine
may decrease the serum concentration of macimorelin
may enhance the serum concentration
may decrease the serum concentration of lenacapavir
they decrease the concentration of buprenorphine in the serum
may reduce the level of serum concentration of abemaciclib
may diminish serum concentrations of CYP3A4 inducers
may diminish the serum concentration when combined with tolvaptan
they decrease the concentration of lurbinectedin in the serum
avanafil: they may diminish the serum concentration of CYP3A4 Inducers
naxitinib: they may diminish the serum concentration of CYP3A4 Inducers
finerenone: they may diminish the serum concentration of CYP3A4 Inducers
infigratinib: they may diminish serum concentrations of CYP3A4 Inducers
leniolisib: they may diminish the serum concentration of CYP3A4 Inducers
selpercatinib: they may diminish the serum concentration of CYP3A4 Inducers
selumetinib: they may diminish the serum concentration of CYP3A4 Inducers
sertraline: they may diminish the serum concentration of CYP3A4 Inducers
tazemetostat: they may diminish the serum concentration of CYP3A4 Inducers
may enhance the concentration of serum when combined with CYP2C8 substrates
may diminish the concentration of serum when combined with isavuconazonium sulfate
may diminish the serum concentration of each other when combined
they decrease the concentration of active metabolites of tamoxifen in serum
trabectedin: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may enhance the effects of the other by pharmacodynamic synergism
may increase the sedative effect
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with inorganic compounds
It may enhance the risk of adverse effects when combined with inorganic compounds
It may enhance the risk of adverse effects when combined with inorganic compounds
propofol: they may enhance the serum concentration of CYP3A4 inducers
propofol: they may enhance the serum concentration of CYP3A4 inducers
propofol: they may enhance the serum concentration of CYP3A4 inducers
propofol: they may enhance the serum concentration of CYP3A4 inducers
propofol: they may enhance the serum concentration of CYP3A4 inducers
may diminish the concentration of serum when combined with cannabis
may diminish the concentration of serum when combined with cannabis
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
when combined, it may increase sedation
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
they decrease the concentration of active metabolites of roflumilast in the serum
when combined, it may increase sedation
may decrease the levels of serum concentration of clozapine
may increase the CNS depressant effect
may increase the serum concentration
hydrocodone/chlorpheniramine/pseudoephedrine
may diminish the serum concentration
may decrease the serum concentration
may decrease the serum concentration of erdafitinib.
may decrease the serum concentration of macitentan
may enhance the serum concentration of macitentan
may decrease the level of serum concentration of pretomanid
CYP3A4 Inducers may decrease the serum concentration of eliglustat
may decrease the serum concentration of encorafenib
may decrease the serum concentration of estazolam
may decrease the serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may diminish the serum concentration of corticosteroids
may increase the hypotensive effect of calcium channel blockers
may diminish the serum concentration of CYP3A4 inducers
may enhance serum concentrations when combined with doxercalciferol
may diminish the serum concentration when combined with nimodipine
may increase the arrhythmogenic effect of Inhalational Anaesthetics
may diminish the serum concentration when combined with CYP2C8 substrates
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
amlodipine: they may diminish the serum concentration of CYP3A4 Inducers
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
istradefylline: they may diminish the serum concentration of CYP3A4 inducers
may enhance the concentration of serum when combined with treprostinil
may diminish the concentration of serum when combined with taurursodiol
nilvadipine: they may diminish the serum concentration of CYP3A4 Inducers
sildenafil: they may diminish the serum concentration of CYP3A4 Inducers
tofacitinib: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the serum concentration of each other when combined
daprodustat: they may enhance the serum concentration of CYP2C8 Inhibitors
CYP2C8 Inhibitors: they may enhance the serum concentration of repaglinide
It may enhance the risk of adverse reactions when combined with Histamine antagonists
buspirone: they may enhance the serum concentration of CYP3A Inhibitors
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine 13-valent
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine heptavalent
It may enhance the risk of adverse effects when combined with Hypnotics
pneumococcal vaccine polyvalent
It may enhance the risk of adverse effects when combined with Hypnotics
It may enhance the risk of adverse effects when combined with CYP3A4 inducers
rolapitant: they may diminish the serum concentration of CYP3A4 Inducers
brimonidine: they may diminish the serum concentration of CYP3A4 Inducers
methylphenidate: they may diminish the serum concentration of CYP3A4 Inducers
molsidomine: they may diminish the serum concentration of CYP3A4 Inducers
dimercaprol: they may diminish the serum concentration of CYP3A4 Inducers
tricyclic antidepressants: they may enhance the serum concentration of CYP3A4 inducers
cannabinoid receptor agonists: they may enhance the serum concentration of CYP3A4 inducers
cannabinoid receptor agonists: they may enhance the serum concentration of CYP3A4 inducers
cinnarizine and dimenhydrinate
this combination will make you feel sleepy or tired when Tranquillisers used in combination
tenofovir disoproxil fumarate or tenofovir DF
may decrease the level of serum concentration
may decrease the level of serum concentration
tovorafenib cannot be taken with strong CYP2C8 Inhibitors
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
CNS depressants increases the toxicity of bupivacaine
Frequency defined:
>10%
Apnea lasting
Hypotension
Injection site pain
1-10%
Arrhythmia
Bradycardia
Tachycardia
Respiratory acidosis
Decreased cardiac output
Rash
<1%
Asystole
Anaphylaxis
Bronchospasm
Pulmonary edema
Thrombosis
Phlebitis
Seizures
Renal tubular toxicity
Pregnancy consideration: </b>B
Lactation: Excreted in the human breast milk
Pregnancy category:
Patient information leaflet
Generic Name: propofol
Pronounced: PROE-poe-fol
Why do we use propofol?
Propofol is used in general anesthesia to induce and sustain unconsciousness during surgical or medical operations, guaranteeing effective sedation for adults and children two months of age and up. It is used as a sedative by slowing down the activity of the nervous system and brain.
Propofol is also used to sedate individuals who are receiving critical care and need assistance with mechanical ventilation (breathing machines).
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
